Nvidia Gains After $20B Groq Licensing Deal for Inference AI

Nvidia, Sidus Space, Coupang, Vanda Pharmaceuticals and ImmuCell

  • Stocks rose midday Friday as U.S. markets reopened after the Christmas holiday, with the S&P 500 hitting a fresh high.
  • NVIDIA agreed to a non‑exclusive licensing deal for its inference technology valued at about $20 billion, lifting its shares nearly 2%.
  • Sidus Space, Coupang, Vanda Pharmaceuticals and ImmuCell all saw notable gains after company‑specific news.

U.S. equities traded higher midday Friday as investors returned after the Christmas holiday and the S&P 500 notched a new all‑time high. Markets showed modest ETF gains: the SPDR S&P 500 ETF (SPY) rose 0.08%, the Invesco QQQ Trust (QQQ) gained 0.16%, and the SPDR Dow Jones Industrial Average ETF Trust (DIA) climbed 0.01%.

- Advertisement -

Nvidia Corp. shares rose nearly 2% after the company entered a non‑exclusive licensing agreement with Groq for its inference technology, a deal valued at about $20 billion. Inference technology is software and models that run trained artificial‑intelligence systems to produce outputs from input data.

Sidus Space Inc. jumped more than 22% midday after the firm was awarded a contract under the Missile Defense Agency’s Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) program. SIDU stock has climbed about 237% over the past five trading sessions.

According to Reuters, Coupang Inc. rose over 9% after the company said that “all leaked customer information has been deleted”; Coupang stated the suspect was a former employee. CPNG is up roughly 10% over the past five trading sessions.

Vanda Pharmaceuticals Inc. gained nearly 8% in premarket trading before settling about 3% higher as investors awaited an upcoming U.S. Food and Drug Administration decision on Tradipitant, a motion‑sickness prevention drug. VNDA is up 7% over five sessions.

- Advertisement -

ImmuCell Corp. rose nearly 10% midday after announcing a 50% expansion of its First Defense field sales force and plans to scale up drug manufacturing; the company also said it is pausing its Re‑Tain treatment for cows after receiving an “Incomplete Letter” from the FDA. ICCC is up about 2% over the past five trading sessions.

✅ Follow BITNEWSBOT on Telegram, Facebook, LinkedIn, X.com, and Google News for instant updates.

Previous Articles:

- Advertisement -

Latest News

US Secretly Buys Russian Microwave Weapons

US Homeland agents reportedly purchased and tested a secret, portable microwave weapon from Russian...

Ether Tops $2K as Derivatives Leverage Hits Record High

Ether surged past $2,000 on Monday as speculative trading intensified, with over 110,000 ETH...

SHIB Surge? 131 Billion Tokens Exit Exchanges

131 billion Shiba Inu tokens have moved away from exchanges, signaling a potential accumulation...

Strategy Buys $1.28B in Bitcoin, Its Largest Buy in a Month

Strategy executed its largest Bitcoin purchase in over a month, spending $1.28 billion to...

Dead Internet Theory Evolves Into ‘Web 4.0’ Rebrand

The "dead internet" conspiracy theory from five years ago, which posits most online content...

Must Read

9 Best Books On Ethereum And Blockchain Technology

QUICK LINKSHow to Choose Your First Blockchain Book: A Simple Framework1. Define Your Goal: Are you looking to Build, Invest, or Understand?2. Assess Your...